Gilead Sciences (GILD) Receives a Buy from Scotiabank

Scotiabank analyst Louise Chen maintained a Buy rating on Gilead Sciences today and set a price target of $177.00.

Claim 50% Off TipRanks Premium

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, Chen is a 4-star analyst with an average return of 2.7% and a 49.49% success rate. Chen covers the Healthcare sector, focusing on stocks such as Merck & Company, Amgen, and Bristol-Myers Squibb.

In addition to Scotiabank, Gilead Sciences also received a Buy from Citi’s Geoff Meacham in a report issued yesterday. However, on February 19, Barclays initiated coverage with a Hold rating on Gilead Sciences (NASDAQ: GILD).

Based on Gilead Sciences’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $7.93 billion and a net profit of $2.18 billion. In comparison, last year the company earned a revenue of $7.57 billion and had a net profit of $1.78 billion

Based on the recent corporate insider activity of 85 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GILD in relation to earlier this year. Most recently, in December 2025, Jeffrey Bluestone, a Director at GILD sold 5,000.00 shares for a total of $625,400.00.